New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Hyperlipoproteinemias
Inclisiran Approval Held Up by Inspection-Related Issues
Inclisiran is a chemically synthesized small interfering RNA that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA.
Statins Tied to Lower In-Hospital COVID-19 Mortality Risk
For adults hospitalized in Spain with COVID-19, treatment with statins associated with lower COVID-19-related mortality
Evolocumab Cuts LDL-C in Pediatric HeFH Patients
The multicenter, double-blind, placebo-controlled HAUSER-RCT study assessed the efficacy and safety of evolocumab in 157 patients aged 10 to 17 years with HeFH.
Coronary Plaque Regression Observed With Icosapent Ethyl
The phase 4 EVAPORATE study assessed the effects of icosapent ethyl on the progression of coronary atherosclerosis in 80 adult patients with elevated triglycerides.
Consistent LDL-C Lowering Reported With Twice-Yearly Inclisiran
The post-hoc analysis included 2 placebo-controlled phase 3 studies (ORION-10 and -11) that evaluated the efficacy and safety of inclisiran sodium in more than 2300 adult patients.
Pitavastatin Effective for Lowering Lipids
Review shows it is more powerful for LDL cholesterol lowering than atorvastatin, rosuvastatin, and fluvastatin.
Evinacumab Gets Priority Review for Homozygous Familial Hypercholesterolemia
Evinacumab is an investigational fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3).
MPR Weekly Dose Podcast Episode 41
This week on the Pod: The FDA issues guidance for COVID-19 vaccine development; Accuracy in COVID-19 antibody testing; How statins may improve outcomes for hospitalized COVID-19 patients; and in non-COVID-related news there’s a new drug approvals in breast cancer and Dravet syndome.
REDUCE-IT: Significant Reduction in Coronary Revascularizations With Icosapent Ethyl
Amarin Corporation announced results from the phase 3 REDUCE-IT study of icosapent ethyl (Vascepa) demonstrating a significant reduction in coronary revascularization procedures in high risk patients with mixed dyslipidemia.
